📰 Final survival results of #PENELOPE-B trial: While routine adjuvant palbociclib cannot be recommended for all HR+/HER2− early breast cancers (BC), the results point to importance of histological subtypes. For lobular BC CDK4/6 inhibition hold new promise: www.annalsofoncology.org/article/S092...